Define_*.

Top updates from #EHA2026 🚨🎥 Watch our exclusive interviews to hear the details: 1️⃣ Findings from MonumenTAL-3: Tal+Dara±Pom versus Dara+Pom+Dex in R/R #MultipleMyeloma - Peter Voorhees (@PlasmaCellPete): ow.ly/oPPw50ZeegL 2️⃣ The Phase III SENTRY trial: selinexor plus ruxolitinib in JAK inhibitor-naïve #myelofibrosis - Claire Harrison (@harrisoncn1): ow.ly/vHYc50ZeegJ 3️⃣ Results from the Phase III FRONTMIND study: tafasitamab, lenalidomide, and R-CHOP in frontline #DLBCL - Umberto Vitolo: ow.ly/H6BT50ZeegI 4️⃣ Long-term results from KOMET-007: ziftomenib with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML - Amer Zeidan (@Dr_AmerZeidan): ow.ly/WaFl50ZeegK 5️⃣ BRUIN CLL-322 trial update: fixed-duration pirtobrutinib plus VR in previously treated CLL - Matthew Davids (@DrMDavids): ow.ly/r55Q50ZeegH #MMSM #Leusm #LYMsm #AMLsm #CLLsm #MPNsm #TrialUpdate #CTSM #ImmunOnc #HemOnc @EHA_Hematology

@pitt9244 垃圾公司 別說內部政治操控了，詐騙集團他們也不處理的

以前半信半疑， 現在深信不疑！ 臉書這一波蒸發 約 316 億美元市值 約 9,500 億台幣 感謝幫出一口氣(合十)

CONGRESS | #EHA2026 | POSTER Naveen Pemmaraju presents long-term results concerning thromboembolic and progression events in patients who enrolled in the phase II REVIVE trial (n = 70) and transitioned to the phase III open-label THRIVE trial (n = 46), evaluating rusfertide in phlebotomy-dependent patients with #PolycythemiaVera. - After >4 years of follow-up, 10% of patients had a thromboembolic event, all of whom had high-risk PV and other risk factors upon study entry. - ~70% of patients with prior thromboembolic events remained event-free while on the study. - The incidence of thromboembolic events was 3/100 PY. - Two of 70 patients had a post-PV progression event. These long-term data provide additional information on the occurrence of thromboembolic and progression events following rusfertide exposure. Longer-term follow-up will continue in the phase III setting. Follow our live feed for more updates: loom.ly/N2uNnTk Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MPN #MPNsm #MedicalCongress @doctorpemm @MDAndersonNews

Episode 29 — AI Biostats etc. x.com/i/broadcasts/1…

Rux and selinexor the first combo to show a survival benefit over rux alone in 1L MF. Also, SVR35 correlating with OS in both arms. Powerful reminder that spleen response is the best established surrogate for OS, as we had argued here: ascopubs.org/doi/10.1200/JC… #EHA26 @harrisoncn1

‼️ #ASCO26 simultaneous publication by Mascarenhas et al: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial Read the full article: bit.ly/3RQ1Eb3

🩸 THE 10 MOST IMPORTANT MALIGNANT HEMATOLOGY TRIALS OF #ASCO26 🧬 LEUKEMIA, MDS & MYELOID MALIGNANCIES 1️⃣ SENTRY (LBA6500) Selinexor + ruxolitinib vs ruxolitinib in frontline myelofibrosis Can XPO1 inhibition improve survival beyond spleen responses? 2️⃣ COMMANDS 3-Year Update (6566) Luspatercept vs epoetin alfa in lower-risk MDS Does early transfusion independence alter long-term outcomes? 3️⃣ IDH1 Triplet Platform (6503) Azacitidine + venetoclax + ivosidenib in IDH1-mutated AML MRD-negative frontline AML strategies continue evolving. 4️⃣ Revumenib Post-SCT Maintenance (6505) Menin inhibition after transplant in KMT2A/NPM1 AML Targeted relapse prevention enters center stage. 5️⃣ Quizartinib Triplet Combo (6504) Quizartinib + decitabine + venetoclax Aggressive FLT3 resistance targeting strategy. 🧠 LYMPHOMA & CLL 6️⃣ frontMIND (LBA7000) Tafasitamab + lenalidomide + R-CHOP in frontline DLBCL A major frontline escalation study. 7️⃣ CONQUER (6508) Dual-epitope anti-CD5 nanobody CAR-T in T-cell malignancies Novel engineering approaches attempt to solve CAR-T fratricide. 💥 MULTIPLE MYELOMA & PLASMA CELL DISORDERS 8️⃣ DREAMM-9 Final Analysis (7503) Belantamab mafodotin + VRd in transplant-ineligible NDMM One of the biggest myeloma presentations at ASCO26. 9️⃣ MajesTEC-9 (LBA7507) Teclistamab vs standard triplets in relapsed/refractory myeloma Bispecifics continue moving earlier. 🔟 SUCCESSOR-2 (LBA7506) Sequencing BCMA vs GPRC5D bispecifics Critical real-world sequencing question. #HemOnc #OncTwitter #ASCO26 #Leukemia #Lymphoma #Myeloma #MedTwitter @ASCO @myesmo @esmo_open @OncoAlert @Larvol

@Komatinsky21199 That’s what I heard from several physicians from Taiwan. There is no practical guideline in using MPN-10 or TSS in real world, it’s not an objective indicator. They only focus on the spleen shrinkage, and they all said any single jak1/2 inhibitor can’t met the needs.

$KPTI RBC consulted KOL and while data didn't hit both coprimary endpoints the KOL is interested in using Selinexor. Estimates 30-40% penetration with NCCN incorporation in guidelines. MF currently a $2B+ market in the U.S.

@tetonbio ashpublications.org/blood/article/…

3/ Selinexor inhibits XPO1, restoring tumor suppressor function and potentially deepening responses when combined with JAK inhibition. Earlier studies showed encouraging spleen and symptom responses, which is why this made it to Phase 3.

$KPTI has 10x+ upside if SENTRY hits. This is a Phase 3 readout of selinexor + ruxolitinib in frontline myelofibrosis, with data expected imminently. The stock is priced for balance sheet stress and low odds, but this is a true binary that can reset the entire story.

@sak77328 @Papa_Heme @VPrasadMDMPH Papa responded. You win.😂

@Papa_Heme @VPrasadMDMPH Let me guess you are gonna get together and complain about Selinexor

Well I can’t wait for @VPrasadMDMPH Vinay Prasad to return back to Twitter. Should make this place interesting again.

@Papa_Heme @sak77328 @VPrasadMDMPH ashpublications.org/bloodadvances/…

@sak77328 @VPrasadMDMPH Nope. No one uses the drug anyways so not too interesting to talk about any more

@pan_accindex @Papa_Heme @VPrasadMDMPH 好噁心的圖

@Papa_Heme @VPrasadMDMPH Nah, all the actually smart people left already. Hanging around simply reflects poorly upon you, “Papa.”

In our latest podcast, Jean-Jacques Kiladjian discusses the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study, presented at #ASH25. Listen here: loom.ly/1GC6gHY #MPN #EssentialThrombocythemia #MPNsm #MedEd @jjkiladjian

CONGRESS | #ASH2025 | POSTER Tiziano Barbui shares real-world findings from a cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV), evaluating ropeginterferon alfa-2b (Ropeg) in patients with polycythemia vera (N = 316). Hematologic response rates improved from 17.9% at baseline to 50.0% at 24 months, with phlebotomy need also declining. Thrombotic events (n=7), disease progression (n=9), secondary cancer (n=3), and deaths (n=3) were infrequent. A total of 88 AEs were reported, including 12 Grade 3–5 events, with SAEs uncommon. Treatment discontinuation reached 20.9% and 31.8% at 12 months and 24 months, respectively. Follow our live feed for more updates: loom.ly/bBHVibw Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #MPN #MPNsm #PolycythemiaVera #MedEd #MedicalCongress @FromBergamo

Sitting here at #ASH25 , I am blown away by the progress in #myeloma in the 21st century. I never thought we could “cure” patients from MM in my lifetime. When I started in the field a quarter century ago, patients would be lucky to make it past 3 years post-diagnosis #mmsm

CONGRESS | #ASH25 | PRESENTATION Jean-Jacques Kiladjian presents 12-month primary endpoint analysis from the ROP-ET phase 3 study of ropeginterferon alfa-2b in patients with essential thrombocytopenia (N = 132). The study met its primary endpoint, 48.0% showed a durable disease response. 62.3% of patients experienced symptom improvement, 25.4% had no disease progression. Safety profile was in live with the experience in PV. TRAEs were mostly mild in 68.9% of patients. Grade ≥3 TRAEs reported in 5.3%. Most common AEs were ALT increase, headache, neutropenia and pruritus. Follow our live feed for more updates: loom.ly/bBHVibw Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #MPN #MPNsm #MedEd #MedicalCongress @jjkiladjian @APHP @Univ_Paris

@MPN_Hub What about white / plt count

CONGRESS | #ASH25 | PRESENTATION Andrew Kuykendall discusses results from Part 1a and Part 1b (Weeks 0–52) of the phase III VERIFY study of rusfertide in #PolycythemiaVera. Of patients randomized to rusfertide (n = 147) or PBO (n = 146) in Part 1a, 274 continued to Part Ib and received open-label rusfertide. Rusfertide continued to provide durable, sustained control of Hct <45% – including in patients who switched to rusfertide from PBO after Week 32 – and phlebotomy eligibility through Week 52. Follow our live feed for more updates: loom.ly/bBHVibw Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #MPN #MPNsm #MedEd #MedicalCongress @KuykendallMd @MoffittNews

@AceTaiwan 請問中國人要怎麼投票🤣🤣

這個根本公開處決，簡直像是在大街被脫褲子，笑死🤣

@Papa_Heme It’s time for patients’ rights. Not defined by any PAPA.

I agree. Time for FDA to review the role of Selinexor in multiple myeloma.